Livermore

Voyager Therapeutics, Inc.

VYGR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001640266

Insider trades, last 90 days

None

  • No open-market purchases or sales were filed in the last 90 days.
View insider trades

13F holders, Q2 2026

135

  • 0 vs. Q1 2026
  • Total value $122.72M
View 13F holders

Superinvestors holding VYGR

0

  • None of the superinvestors held VYGR at the end of Q2 2026.
See all holders

Price chart

Latest insider trades

View all: Latest insider trades

Open-market purchases and sales by VYGR insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Apr 3, 2026Apr 2, 2026Sandrock AlfredPresident and CEOSSaleCommon Stock−11.51K$3.87−$44.55K472.55K−2.4%SEC10b5-1
Feb 26, 2026Feb 24, 2026Swartz RobinCOO & CBOSSaleCommon Stock−6.46K$3.77−$24.35K199.74K−3.1%SEC10b5-1
Feb 26, 2026Feb 24, 2026Sandrock AlfredPresident and CEOSSaleCommon Stock−14.2K$3.79−$53.81K484.06K−2.8%SEC10b5-1
Feb 26, 2026Feb 24, 2026Jorgensen Nathan D.Chief Financial OfficerSSaleCommon Stock−4.67K$3.77−$17.6K151.42K−3.0%SEC10b5-1
Feb 26, 2026Feb 24, 2026Carter Todd AlfredChief Scientific OfficerSSaleCommon Stock−4.17K$3.76−$15.69K145.72K−2.8%SEC10b5-1

Top 5 13F holders, Q2 2026

View all: Top 5 13F holders, Q2 2026

The largest institutional positions in VYGR at the end of Q2 2026.

Institutions holding VYGR in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.5,172,063$18.1M0.00%−396,318−7.1%Reduced
MILLENNIUM MANAGEMENT LLC4,442,951$15.55M0.01%+1,014,380+29.6%Added
ARMISTICE CAPITAL, LLC3,436,000$12.03M0.33%−64,000−1.8%Reduced
Vestal Point Capital, LP2,625,000$9.19M0.21%−377,936−12.6%Reduced
VANGUARD CAPITAL MANAGEMENT LLC2,345,674$8.21M0.00%+62,421+2.7%Added